Bradley Foster & Sargent Inc. CT trimmed its holdings in Danaher Co. (NYSE:DHR – Free Report) by 0.1% in the 4th quarter, Holdings Channel reports. The fund owned 605,423 shares of the conglomerate’s stock after selling 569 shares during the quarter. Danaher accounts for about 2.3% of Bradley Foster & Sargent Inc. CT’s investment portfolio, making the stock its 6th biggest position. Bradley Foster & Sargent Inc. CT’s holdings in Danaher were worth $138,975,000 at the end of the most recent quarter.
Several other hedge funds have also bought and sold shares of DHR. Kovack Advisors Inc. lifted its holdings in Danaher by 3.4% during the third quarter. Kovack Advisors Inc. now owns 1,243 shares of the conglomerate’s stock worth $346,000 after buying an additional 41 shares during the period. Gilbert & Cook Inc. raised its position in shares of Danaher by 2.5% in the 4th quarter. Gilbert & Cook Inc. now owns 1,749 shares of the conglomerate’s stock worth $401,000 after acquiring an additional 42 shares in the last quarter. Grimes & Company Inc. boosted its position in Danaher by 0.6% during the fourth quarter. Grimes & Company Inc. now owns 7,390 shares of the conglomerate’s stock valued at $1,696,000 after purchasing an additional 43 shares in the last quarter. Harbour Investments Inc. boosted its position in Danaher by 3.0% during the third quarter. Harbour Investments Inc. now owns 1,531 shares of the conglomerate’s stock valued at $426,000 after purchasing an additional 45 shares in the last quarter. Finally, Dakota Community Bank & Trust NA raised its holdings in Danaher by 16.4% in the fourth quarter. Dakota Community Bank & Trust NA now owns 320 shares of the conglomerate’s stock worth $73,000 after purchasing an additional 45 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.
Insider Buying and Selling at Danaher
In related news, SVP Brian W. Ellis sold 5,700 shares of Danaher stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $224.13, for a total value of $1,277,541.00. Following the sale, the senior vice president now owns 20,230 shares of the company’s stock, valued at approximately $4,534,149.90. This trade represents a 21.98 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 11.10% of the stock is owned by corporate insiders.
Analyst Ratings Changes
View Our Latest Stock Analysis on Danaher
Danaher Trading Up 1.5 %
Danaher stock opened at $208.10 on Friday. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. The firm has a market cap of $150.31 billion, a PE ratio of 39.41, a P/E/G ratio of 2.61 and a beta of 0.83. The stock’s 50 day simple moving average is $227.21 and its two-hundred day simple moving average is $247.52. Danaher Co. has a 12 month low of $196.80 and a 12 month high of $281.70.
Danaher (NYSE:DHR – Get Free Report) last released its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, meeting the consensus estimate of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same quarter last year, the firm earned $2.09 EPS. Analysts anticipate that Danaher Co. will post 7.67 earnings per share for the current year.
Danaher Increases Dividend
The firm also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 0.62%. This is an increase from Danaher’s previous quarterly dividend of $0.27. Danaher’s dividend payout ratio is currently 20.45%.
Danaher Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Further Reading
- Five stocks we like better than Danaher
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- These 3 Defensive Retail Stocks Are Outpacing the Market
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Ray Dalio’s Bridgewater Loaded Up on These Stocks in Q4 2024
- Comparing and Trading High PE Ratio Stocks
- Walmart Faces Tariff Headwinds, Consumer Trends Remain Positive
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.